Reminder of Gossamer Bio Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 52 minutes ago
0mins
Should l Buy GOSS?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Case Background: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study, resulting in investor losses when the true information was revealed, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.339
Low
10.00
Averages
12.33
High
15.00
Current: 0.339
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Case Background: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study, resulting in investor losses when the true information was revealed, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors having until June 1, 2026, to apply as Lead Plaintiff.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence.
- Legal Firm Reputation: Pomerantz LLP is recognized as a leading firm in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling complex legal cases.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the class period from February 2025 to February 2026, potentially leading to restructuring and negatively impacting future financial performance.
- New Era Energy Violations: New Era Energy & Digital, Inc. faces allegations of overstating progress on its Texas data center project and engaging in fraudulent schemes to evade liabilities, which could result in materially misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that prior positive statements were misleading, potentially harming its market reputation.
- Medpace Holdings Performance Inflation: Medpace Holdings, Inc. is accused of making false statements regarding its projected book-to-bill ratio for Q4 2025, failing to adequately assess the impact of cancellations, which may lead to diminished investor confidence in the company's future performance.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, alleging that misleading information led to inflated stock prices.
- False Statements Revealed: The lawsuit claims that Gossamer provided overly positive statements regarding its Phase 3 PROSERA study for treating pulmonary arterial hypertension while concealing significant adverse facts about the study design, particularly regarding placebo response control at Latin American sites, misleading investors.
- Investor Rights Protection: Affected investors must apply by June 1, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and potential claims.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit due to its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Investor Losses: Hagens Berman law firm is urging investors who suffered significant losses during the class period to submit their claims, suggesting that this event could trigger widespread investor compensation claims, further impacting the company's financial health.
- Regulatory Scrutiny: The lawsuit alleges improper disclosures regarding trial design and patient recruitment, potentially leading to increased regulatory scrutiny, which could affect the company's future financing and market credibility.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, resulting in artificially inflated stock prices that led investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating that the lawsuit provides an opportunity for recovery of losses without requiring lead plaintiff status to share in any potential recovery.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they successfully recover losses, thereby reducing the financial burden on investors.
See More
Reminder of Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Case Background: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study, resulting in investor losses when the true information was revealed, highlighting the company's lack of transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors having until June 1, 2026, to apply as Lead Plaintiff.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance, which did not meet the required 0.025 alpha threshold.
- Stock Price Plunge: Following the disappointing clinical trial results, Gossamer's stock price fell by $1.71, or 80.13%, closing at $0.42 per share on February 23, 2026, indicating a significant loss of investor confidence.
- Legal Firm Reputation: Pomerantz LLP is recognized as a leading firm in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise in handling complex legal cases.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the class period from February 2025 to February 2026, potentially leading to restructuring and negatively impacting future financial performance.
- New Era Energy Violations: New Era Energy & Digital, Inc. faces allegations of overstating progress on its Texas data center project and engaging in fraudulent schemes to evade liabilities, which could result in materially misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that prior positive statements were misleading, potentially harming its market reputation.
- Medpace Holdings Performance Inflation: Medpace Holdings, Inc. is accused of making false statements regarding its projected book-to-bill ratio for Q4 2025, failing to adequately assess the impact of cancellations, which may lead to diminished investor confidence in the company's future performance.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, alleging that misleading information led to inflated stock prices.
- False Statements Revealed: The lawsuit claims that Gossamer provided overly positive statements regarding its Phase 3 PROSERA study for treating pulmonary arterial hypertension while concealing significant adverse facts about the study design, particularly regarding placebo response control at Latin American sites, misleading investors.
- Investor Rights Protection: Affected investors must apply by June 1, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and potential claims.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit due to its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Investor Losses: Hagens Berman law firm is urging investors who suffered significant losses during the class period to submit their claims, suggesting that this event could trigger widespread investor compensation claims, further impacting the company's financial health.
- Regulatory Scrutiny: The lawsuit alleges improper disclosures regarding trial design and patient recruitment, potentially leading to increased regulatory scrutiny, which could affect the company's future financing and market credibility.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, resulting in artificially inflated stock prices that led investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating that the lawsuit provides an opportunity for recovery of losses without requiring lead plaintiff status to share in any potential recovery.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they successfully recover losses, thereby reducing the financial burden on investors.
See More
